Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes ; volume:1 ; number:2 ; day:19 ; month:1 ; year:2011 ; pages:45-56 ; date:12.2010
Diabetes therapy ; 1, Heft 2 (19.1.2011), 45-56, 12.2010
- Creator
-
Tahrani, Abd A.
Barnett, Anthony H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-010-0007-3
- URN
-
urn:nbn:de:101:1-2411120918524.751745850308
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tahrani, Abd A.
- Barnett, Anthony H.
- SpringerLink (Online service)
Other Objects (12)
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?